VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Joie Armstrong asked her doctor about taking a GLP-1 medication to help her lose weight six times before she got a prescription, and then was denied coverage by her insurance company. Adrian, a ...

Glucagon-like peptide-1 (GLP-1) injections such as Wegovy (semaglutide) and Zepbound (tirzepatide) are the most effective weight-loss medications available today. Oral GLP-1 pills, such as ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ethical issues and prices that are still too high for many patients.

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

The World Health Organization continues its investigation into the origins of COVID-19, with significant information still needed. Concurrently, Americans like Amy Spencer are crafting their own ...

The WHO continues to probe COVID-19 origins, yet critical information is lacking. Meanwhile, individuals like Amy Spencer are ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

The market for weight management medicines has been the hottest therapeutic area in the past two years. The pharmaceutical ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...